Attached files
file | filename |
---|---|
EX-32.1 - EX-32.1 - Nabriva Therapeutics plc | a18-14107_1ex32d1.htm |
EX-31.2 - EX-31.2 - Nabriva Therapeutics plc | a18-14107_1ex31d2.htm |
EX-31.1 - EX-31.1 - Nabriva Therapeutics plc | a18-14107_1ex31d1.htm |
10-Q - 10-Q - Nabriva Therapeutics plc | a18-14107_110q.htm |
CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Quarterly Report on Form 10-Q of Nabriva Therapeutics plc (the Company) for the period ended June 30, 2018 as filed with the Securities and Exchange Commission on the date hereof (the Report), the undersigned, Gary Sender, Chief Financial Officer of the Company, hereby certifies, pursuant to 18 U.S.C. Section 1350, that to his knowledge:
(1) the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
/s/ Gary Sender |
|
|
|
Gary Sender |
|
Chief Financial Officer |
|
(Principal Financial Officer) |
|
|
|
Dated: August 9, 2018 |
|